Formulation and Evaluation of Lamivudine Nanosuspension
Abstract
The present research aimed to develop & Evaluation of Lamivudine Nanosuspension. Lamivudine is a potent in vitro inhibitor of human immune deficiency virus belongs to the category of anti-retroviral drugs. The formulated Nanosuspension was subjected to various evaluation parameters like particle size, polydispersity index, zeta potential, drug content, viscosity, saturation solubility studies, In vitro release, treatment of kinetic data, and stability studies. The polydispersity ranged from 0.218 PDI to 0.331 PDI and zeta potential ranged from -1.60 mV to -4.79 mV are the important evaluation parameters are responsible for the stability of nanosuspensions. The Polydispersity index presents the quantity of particle size distribution ranges from 452.4 nm to 532.2 nm. In this result, LNSF4 shows spectacular drug content range of 86±1.8% to 97±2.5% it is the maximum drug content. The Brook field viscometer to determine the viscosity of Lamivudine Nano suspension of different formulations was found to be 44.4±2.1 cps to 87.7±1.4 cps. The general Nanosuspension formulations LNSF4 shows 98.64 % better controlled released in comparison with abundant formulation. In all the cases the best-fit model encounter uoto be peppas with ‘n’ value between 0.768 to 0.917. The ‘n’ value of formulation LNSF4 was 0.876 and suggesting so the drug was released by Zero-order kinetics. Acceleration stability studies intermediate storage condition has been changed from 30°C ± 2°C and 60% RH ± 5% Relative Humidity. After a 90 days study it revolves that there’s no change in Drug content, In vitro drug release, and particle size.
Keywords: Lamivudine, Nanosuspension, Saturation solubility, Scanning Electron Microscopy, Stability study.
Keywords:
Lamivudine, Nanosuspension, Saturation solubility, Scanning Electron Microscopy, Stability studyDOI
https://doi.org/10.22270/jddt.v11i4-S.4961References
Witika BA, Smith VJ, Walker RB, Quality by Design Optimization of Cold Sonochemical Synthesis of Zidovudine-Lamivudine Nanosuspensions, Pharmaceutics, 2020; 12(4): 367-379. https://doi.org/10.3390/pharmaceutics12040367
Chakravarty M, Vora A, Nanotechnology-based antiviral therapeutics. Drug Delivery and Translational Research, 2021; 11(3):748-787. https://doi.org/10.1007/s13346-020-00818-0
Mothilal M, Krishna M, chaitanya Teja, Surya SP, Manimaran V, Damodharan N, Formulation and evaluation of naproxen-eudragita RS 100 nanosuspension using 32 factorial design, International Journal of Pharmacy and Pharmaceutical Sciences, 2014; 6(7):449-455.
Sakshi Taneja, Satish Shilpi, Kapil Khatri, Formulation and optimization of efavirenz nanosuspensions using the precipitation ultrasonication technique for solubility enhancement, Artificial Cells, Nanomedicine and Biotechnology, 2016; 44(3):978-984.
Viswanatha Reddy M, Saravana Kumar K, Ramesh Y, Chanukya Kumar G, Venkateswarlu I, Venkatesh R, Preparation And Evaluation Of Quetiapine Fumarate Microspheres, Journal of Pharmacy Research, 2011; 4(11):4164-4166.
Jacob S, Nair A B, Shah J, Emerging role of nanosuspensions in drug delivery systems. Biomaterials Research, 2020; 24(3):1-16 https://doi.org/10.1186/s40824-020-0184-8
Alukda D, Sturgis T, Youan BC, Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention, Journal of Pharmaceutical Sciences, 2011; 100(8):3345-3356. https://doi.org/10.1002/jps.22529
Ahuja BK, Jena SK, Paidi SK, Bagri S, Suresh S. Formulation, Optimization and in Vitro-in Vivo Evaluation of Febuxostat Nanosuspension. International Journal of Pharmaceutics, 2015; 478(2): 540-552. https://doi.org/10.1016/j.ijpharm.2014.12.003
Praveen G, Parameswari A, Formulation and In-vitro Evaluation of Moxifloxacin Microspheres Using Natural Polysaccharides. Future Journal of Pharmaceuticals and Health Sciences, 2021; 1(1):24-28.
Rajesh B Nawale, Uday A Deokate, Sandhana R Shahi, Pradeep M, Lokhande, Formulation and Characterization of Efavirenz Nanosuspension by QbD approach, Research Journal of Pharmacy and Technology, 2017; 10(9):2960-2972. https://doi.org/10.5958/0974-360X.2017.00525.X
Naga Durga Mani Achyath S V, Saibabu CH, Malyadri T, Formulation and Invitro Characterization of Fluvoxamine Loaded Nanoparticles. International Journal of Health Care and Biological Sciences, 2021; 2(2):43-52. https://doi.org/10.46795/ijhcbs.vi.160
Salem H F, Sustained-release progesterone nanosuspension following intramuscular injection in ovariectomized rats. International Journal of Nanomedicine, 2010; 5:943-954. https://doi.org/10.2147/IJN.S12947
Muniraja Lakshmi K, Kiran M, Sai Prasanna K, Appa Rao, Formulation and Characterization of Silver Nanoparticles Loaded with Aqueous Extract of Lantana Camara Linn Leaves, Future Journal of Pharmaceuticals and Health Sciences, 2021; 1(2):21-28.
Permana A D, McCrudden M T C, Donnelly R F, Enhanced Intradermal Delivery of Nanosuspensions of Antifilariasis Drugs Using Dissolving Microneedles: A Proof of Concept Study, Pharmaceutics, 2019; 11(7):3-22. https://doi.org/10.3390/pharmaceutics11070346
Verma S, Gokhale R, Burgess DJ. Pharmaceutical Nanotechnology A Comparative Study of Top-down and Bottom-up Approaches for the Preparation of Micro / Nanosuspensions. 2009; 380:216-222. https://doi.org/10.1016/j.ijpharm.2009.07.005
McConnachie LA, Kinman LM, Koehn J, Kraft JC, Lane S, Lee W, Collier AC, Ho RJY. Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection. Journal of Pharmaceutical Sciences, 2018; 107(7):1787-1790. https://doi.org/10.1016/j.xphs.2018.03.005
Published
Abstract Display: 2331 
PDF Downloads: 1480 PDF Downloads: 340 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.